<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Calcium citrate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Calcium citrate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Calcium citrate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8829" href="/d/html/8829.html" rel="external">see "Calcium citrate: Drug information"</a> and <a class="drug drug_patient" data-topicid="11305" href="/d/html/11305.html" rel="external">see "Calcium citrate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F144542"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cal-Citrate [OTC];</li>
<li>Calcitrate [OTC] [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1002942"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Calcium Salt</span>;</li>
<li>
<span class="list-set-name">Electrolyte Supplement, Oral</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812487"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Calcium citrate 1,000 mg = 211 mg <b>elemental </b>calcium = 10.5 mEq calcium</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cff57115-d7c6-4e8a-b035-54db82ca3ddb">Hypocalcemia, asymptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypocalcemia, asymptomatic:</b> Limited data available: Infants, Children, and Adolescents: Dose expressed as <b>elemental calcium</b>: Oral: 30 to 75 mg/kg/day in 4 to 5 divided doses (Lynch 2017; Root 2020).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729624"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Initiate at the lowest dose of the recommended dosage range; monitor serum calcium concentrations closely. Accumulation may occur with renal impairment and subsequent doses may require adjustment based on serum calcium concentrations.</p></div>
<div class="block dohp drugH1Div" id="F52729625"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. No initial dosage adjustment necessary; subsequent doses should be guided by serum calcium concentrations.</p></div>
<div class="block doa drugH1Div" id="F144546"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8829" href="/d/html/8829.html" rel="external">see "Calcium citrate: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>One gram of calcium <b>citrate</b> is equal to 211 mg of <b>elemental</b> calcium.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3dffe3ee-ff84-43e7-8c7a-771424a85242">Calcium supplementation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Calcium supplementation (OTC labeling):</b>
<b>Oral:</b> 200 mg to 1 g/day (as <b>elemental</b> calcium) as a single dose or in divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>The recommended daily intake of <b>elemental</b> calcium (from dietary sources and supplemental sources if needed) for optimal bone health is 1.2 g/day (postmenopausal women) or 1 to 1.2 g/day in other adults. It is preferred to obtain these daily amounts primarily through dietary sources. There is no evidence that intakes higher than these improve bone strength (AACE [Camacho 2020]; ES [Watts 2012]; IOM 2011; NOF [Cosman 2014]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ede8ee5-8caf-477b-96c4-c9dc1e709379">Hypocalcemia, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypocalcemia, chronic (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use of IV calcium may be required in patients who become unable to take or absorb oral calcium. Vitamin D replacement may also be required depending on the cause of hypocalcemia (eg, hypoparathyroidism, vitamin D deficiency) . Correct concurrent hypomagnesemia if present (ES [Bilezikian 2016]; Fong 2012). These recommendations <b>do not</b> apply to patients with chronic kidney disease; refer to specific dosing recommendations in this population (eg, for hyperphosphatemia).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 1 to 2 g/day of <b>elemental</b> calcium administered in 2 to 3 divided doses; adjust dose as needed to control symptoms and maintain albumin-corrected calcium levels in the low-normal range (ES [Bilezikian 2016]; Goltzman 2022a).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="06e1c01e-763b-4c47-be91-51edcc050efe">Hypoparathyroidism, acute postsurgical, mild</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoparathyroidism, acute postsurgical, mild (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use in patients with mild symptoms (eg, oral paresthesias) and/or an albumin-corrected serum calcium level below normal but ≥7.5 mg/dL (≥1.87 mmol/L); use of IV calcium is required in patients with more severe symptoms of hypocalcemia, patients unable to take or absorb oral calcium, or patients whose symptoms do not improve with oral therapy. Correct concurrent hypomagnesemia if present and initiate vitamin D replacement as soon as feasible (ES [Bilezikian 2016]; Fong 2012; Goltzman 2022b).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 1 to 4 g/day of <b>elemental</b> calcium administered in 2 to 3 divided doses; adjust dose as needed to control symptoms and maintain albumin-corrected calcium levels in the low-normal range (ES [Bilezikian 2016]; Goltzman 2022b). <b>Note:</b> Postsurgical hypoparathyroidism may be transient; attempt a slow taper of calcium and vitamin D supplements starting 3 to 6 weeks after surgery (Goltzman 2022b).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block adr drugH1Div" id="F144525"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;margin-left:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined. Mild hypercalcemia (calcium: &gt;10.5 mg/dL) may be asymptomatic or manifest as anorexia, constipation, nausea, and vomiting. More severe hypercalcemia (calcium: &gt;12 mg/dL) is associated with coma, confusion, delirium, and stupor.</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Headache</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Hypercalcemia, hypophosphatemia, increased thirst</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal pain, anorexia, constipation, nausea, vomiting</p></div>
<div class="block war drugH1Div" id="F144522"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: Constipation, bloating, and gas are common with calcium supplements (especially carbonate salt).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypercalcemia: Chronic hypercalcemia may result in generalized vascular and soft tissue calcification, exacerbate nephrolithiasis, and has been associated with increased mortality in adults with chronic kidney disease (CKD) (KDIGO 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Achlorhydria: Calcium absorption is impaired in achlorhydria; common in elderly. Citrate may be preferred because better absorbed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoparathyroid disease: Hypercalcemia and hypercalciuria are most likely to occur in hypoparathyroid patients receiving high doses of vitamin D.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney stones (calcium-containing): Use caution when administering calcium supplements to patients with a history of kidney stones.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal failure to avoid hypercalcemia; frequent monitoring of serum calcium and phosphorus is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate product selection: Multiple salt forms of calcium exist; close attention must be paid to the salt form when ordering and administering calcium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over or under dosing.</p></div>
<div class="block dosfc drugH1Div" id="F21879434"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">1 g calcium citrate = elemental calcium 211 mg = calcium 10.5 mEq = calcium 5.25 mmol</p></div>
<div class="block foc drugH1Div" id="F144531"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as citrate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cal-Citrate: 150 mg [dye free]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Granules, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 760 mg/3.5 g (480 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1040 mg [DSC], 250 mg (elemental calcium)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Calcitrate: 200 mg (elemental calcium) [DSC] [lactose free, milk derivatives/products, no artificial color(s), no artificial flavor(s), sodium free, soy free, sugar free, wheat free, yeast free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 mg (elemental calcium)</p></div>
<div class="block geq drugH1Div" id="F144518"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323033"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Calcium Citrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">950 (200 Ca) mg (per each): $0.04</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adip drugH1Div" id="F53565665"><span class="drugH1">Additional Information</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Elemental Calcium Content of Calcium Salts</b></caption>
<colgroup><col align="left"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Calcium Salt</p></th>
<th align="center">
<p style="text-indent:0em;">Elemental Calcium</p>
<p style="text-indent:0em;">(mg/1 g of salt form)</p></th>
<th align="center">
<p style="text-indent:0em;">Calcium</p>
<p style="text-indent:0em;">(mEq/g)</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium acetate</p></td>
<td align="center">
<p style="text-indent:0em;">253</p></td>
<td align="center">
<p style="text-indent:0em;">12.7</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium carbonate</p></td>
<td align="center">
<p style="text-indent:0em;">400</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium chloride</p></td>
<td align="center">
<p style="text-indent:0em;">273</p></td>
<td align="center">
<p style="text-indent:0em;">13.6</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium citrate</p></td>
<td align="center">
<p style="text-indent:0em;">211</p></td>
<td align="center">
<p style="text-indent:0em;">10.5</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium glubionate</p></td>
<td align="center">
<p style="text-indent:0em;">63.8</p></td>
<td align="center">
<p style="text-indent:0em;">3.2</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium gluconate</p></td>
<td align="center">
<p style="text-indent:0em;">93</p></td>
<td align="center">
<p style="text-indent:0em;">4.65</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium lactate</p></td>
<td align="center">
<p style="text-indent:0em;">130</p></td>
<td align="center">
<p style="text-indent:0em;">6.5</p></td></tr></tbody></table></div>
<div class="block admp drugH1Div" id="F52612347"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer with or without food (AAP [Golden 2014]; Straub 2007). Administration with food may increase absorption (Straub 2007).</p></div>
<div class="block adm drugH1Div" id="F50753666"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">May administer with or without food; administration with food may increase absorption. Doses &gt;600 mg (<b>elemental</b> calcium) per day should be divided for optimal absorption (AACE [Camacho 2020]).</p></div>
<div class="block sts drugH1Div" id="F25188718"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at room temperature. </p></div>
<div class="block usep drugH1Div" id="F53565805"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Dietary supplement (FDA approved in adults); has also been used for treatment of hypocalcemia.</p></div>
<div class="block mst drugH1Div" id="F144560"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Citracal may be confused with Citrucel</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298939"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F144526"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: Calcium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Calcium Salts.  Management: Separate administration of alpha-lipoic acid from that of any calcium-containing compounds by several hours. If alpha-lipoic acid is given 30 minutes before breakfast, then administer oral calcium-containing products at lunch or dinner.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: Calcium Salts may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with calcium salts under fed conditions, but coadministration with or 2 hours after a calcium salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir.  Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Calcium Salts may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Calcium Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral calcium. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral calcium salts. Alternatively, dolutegravir and oral calcium can be taken together with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir.  Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estramustine: Calcium Salts may decrease the absorption of Estramustine.  Management: Administer estramustine on an empty stomach, at least 1 hour before or 2 hours after the dose of an oral calcium supplement. If coadministered with calcium salts, monitor for decreased estramustine therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Calcium Salts may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May increase the serum concentration of Calcium Salts. Calcium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, calcium salts may impair the absorption of fluoride. Management: Avoid eating or drinking dairy products or consuming vitamins or supplements with calcium salts one hour before or after of the administration of fluoride.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE.  Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.  Management: This applies only to oral phosphate and calcium administration. Administering oral phosphate supplements as far apart from the administration of an oral calcium salt as possible may be able to minimize the significance of the interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Calcium Salts may decrease the absorption of Quinolones. Of concern only with oral administration of both agents.  Management: Consider administering an oral quinolone at least 2 hours before or 6 hours after the dose of oral calcium to minimize this interaction. Monitor for decreased therapeutic effects of quinolones during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir.  Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat.  Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: Calcium Salts may decrease the serum concentration of Tetracyclines.  Management: If coadministration of oral calcium with oral tetracyclines cannot be avoided, consider separating administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May increase the serum concentration of Calcium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine.  Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F50931255"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">
<b>Dietary reference intake for calcium (IOM 2011): </b></p>
<p style="text-indent:-2em;margin-left:4em;">0 to &lt;6 months: Adequate intake: 200 mg <b>elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:4em;">6 to 12 months: Adequate intake: 260 mg <b>elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 3 years: Recommended dietary allowance (RDA): 700 mg <b>elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:4em;">4 to 8 years: RDA: 1,000 mg <b>elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:4em;">9 to 18 years: RDA: 1,300 mg <b>elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:4em;">19 to 50 years: RDA: 1,000 mg <b>elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:4em;">51 to 70 years: RDA:</p>
<p style="text-indent:-2em;margin-left:6em;">Females: 1,200 mg <b>elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:6em;">Males: 1,000 mg <b>elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;70 years: RDA: 1,200 mg<b> elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:4em;">Pregnancy/Lactating: RDA: Requirements are the same as in nonpregnant or nonlactating females.</p></div>
<div class="block pri drugH1Div" id="F13333812"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Calcium crosses the placenta. Intestinal absorption of calcium increases during pregnancy. The amount of calcium reaching the fetus is determined by maternal physiological changes. Calcium requirements are the same in pregnant and nonpregnant females (IOM 2011).</p></div>
<div class="block mopp drugH1Div" id="F53565786"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum calcium (ionized calcium preferred if available), phosphate, magnesium.</p></div>
<div class="block rerp drugH1Div" id="F53565666"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Ranges may slightly vary by individual laboratories.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Normal Calcium Values (Lo 2020)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center"></th>
<th align="center">
<p style="text-indent:0em;">
<b>Age</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Serum Concentration</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center" rowspan="6">
<p style="text-indent:0em;">Calcium, total</p></td>
<td align="center">
<p style="text-indent:0em;">Cord blood</p></td>
<td align="center">
<p style="text-indent:0em;">9 to 11.5 mg/dL (SI: 2.3 to 2.9 mmol/L)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Newborn 3 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">9 to 10.6 mg/dL (SI: 2.3 to 2.7 mmol/L)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Newborn 24 to 48 hours</p></td>
<td align="center">
<p style="text-indent:0em;">7 to 12 mg/dL (SI: 1.8 to 3 mmol/L)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">4 to 7 days</p></td>
<td align="center">
<p style="text-indent:0em;">9 to 10.9 mg/dL (SI: 2.3 to 2.7 mmol/L)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Child</p></td>
<td align="center">
<p style="text-indent:0em;">8.8 to 10.8 mg/dL (SI: 2.2 to 2.7 mmol/L)</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Adolescent to Adult</p></td>
<td align="center">
<p style="text-indent:0em;">8.4 to 10.2 mg/dL (SI: 2.1 to 2.6 mmol/L)</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">Calcium, ionized</p></td>
<td align="center">
<p style="text-indent:0em;">Cord blood</p></td>
<td align="center">
<p style="text-indent:0em;">5 to 6 mg/dL</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Newborn 3 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">4.3 to 5.1 mg/dL</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Newborn 24 to 48 hours</p></td>
<td align="center">
<p style="text-indent:0em;">4 to 4.7 mg/dL</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">≥2 days</p></td>
<td align="center">
<p style="text-indent:0em;">4.8 to 4.92 mg/dL</p>
<p style="text-indent:0em;">(2.24 to 2.46 mEq/L)</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">In low albumin states if ionized calcium is unavailable, the corrected <b>total </b>serum calcium may be estimated by this equation (assuming a normal albumin of 4 g/dL [SI: 40 g/L]):</p>
<p style="text-indent:-2em;margin-left:4em;">Corrected total calcium (mg/dL) = measured serum calcium (mg/mL) + 0.8 (4 − measured serum albumin [g/dL])</p></div>
<div class="block pha drugH1Div" id="F144521"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Moderates nerve and muscle performance via action potential excitation threshold regulation</p></div>
<div class="block phk drugH1Div" id="F144534"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: 25% to 35%, requires vitamin D; varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, young adults 25%); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 45% </p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily in the feces as unabsorbed calcium </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F144538"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Calcimax | Calcimax forte | Calcional citrato | Citramar | Citramar nf</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Miocalven</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Calcimax | Calcimax forte</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Si te li</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Citrato de calcio</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bioherba calcium citrate | Calcitrat | Calcium | Calcium citrat | Calcium du pharma | Calciumcitrat | Encormed aktiv calcium | Sanguvit calciumcitrat</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Calasorb calcium | Vega calcium citrate</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Citracal</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Citrokalcium</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Free Cal</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Calcite | Pluscal</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ci-cal | Solaray calcium citrate</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Calcii citras | Calcitrat</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Kalcija citrats</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Calcival | Tero</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Citracal | Solaray calcium citrate</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Calcium citrate windmill</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Calcitrate</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Citrato de calcio | Gadocal | Gnc calcium citrate</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Calcit ultra | Citracal</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cal Cit | Cal-med | Calcipac | Calsorp</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Belecal | Calbo | Calbone | Calcik | Calcitrate | Callate | Catin | Cenca | Ecical | Free Cal | Jia Cal | Livingca | Mei Cal | Ucocal</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Calcimax</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Calcitrex | Citracal | Citrato de calcio</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26938200">
<a name="26938200"></a>Bilezikian JP, Brandi ML, Cusano NE, et al. Management of hypoparathyroidism: present and future. <i>J Clin Endocrinol Metab</i>. 2016;101(6):2313-2324. doi:10.1210/jc.2015-3910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-citrate-pediatric-drug-information/abstract-text/26938200/pubmed" id="26938200" target="_blank">26938200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26160136">
<a name="26160136"></a>Bollerslev J, Rejnmark L, Marcocci C, et al; European Society of Endocrinology. European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. <i>Eur J Endocrinol</i>. 2015;173(2):G1-G20. doi:10.1530/EJE-15-0628<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-citrate-pediatric-drug-information/abstract-text/26160136/pubmed" id="26160136" target="_blank">26160136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26943719">
<a name="26943719"></a>Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypoparathyroidism: summary statement and guidelines. <i>J Clin Endocrinol Metab</i>. 2016;101(6):2273-2283. doi:10.1210/jc.2015-3907<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-citrate-pediatric-drug-information/abstract-text/26943719/pubmed" id="26943719" target="_blank">26943719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9690425">
<a name="9690425"></a>Bushinsky DA, Monk RD. Electrolyte quintet: calcium. <i>Lancet</i>. 1998;352(9124):306-311. doi:10.1016/s0140-6736(97)12331-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-citrate-pediatric-drug-information/abstract-text/9690425/pubmed" id="9690425" target="_blank">9690425</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Cal-Citrate (calcium citrate) [prescribing information]. Fayetteville, AR: Bio-Tech.</div>
</li>
<li>
<div class="reference">
                  Calcium citrate caplets [prescribing information]. Tigard, OR: Magno-Humphries Labs.</div>
</li>
<li>
<div class="reference">
                  Calcium citrate caplets [prescribing information]. Tempe, AZ: 21st Century HealthCare Inc.</div>
</li>
<li>
<div class="reference">
                  Calcium citrate granules [prescribing information]. Long Island City, NY: Freeda Vitamins Inc.</div>
</li>
<li>
<div class="reference">
                  Calcium citrate tablets [prescribing information]. West Caldwell, NJ: Windmill Health Products; received November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32427503">
<a name="32427503"></a>Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. <i>Endocr Pract</i>. 2020;26(suppl 1):s1-s46. doi:10.4158/GL-2020-0524SUPPL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-citrate-pediatric-drug-information/abstract-text/32427503/pubmed" id="32427503" target="_blank">32427503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25182228">
<a name="25182228"></a>Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R; National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi:10.1007/s00198-014-2794-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-citrate-pediatric-drug-information/abstract-text/25182228/pubmed" id="25182228" target="_blank">25182228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30907953">
<a name="30907953"></a>Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-citrate-pediatric-drug-information/abstract-text/30907953/pubmed" id="30907953" target="_blank">30907953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22439169">
<a name="22439169"></a>Fong J, Khan A. Hypocalcemia: updates in diagnosis and management for primary care. <i>Can Fam Physician</i>. 2012;58(2):158-162.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-citrate-pediatric-drug-information/abstract-text/22439169/pubmed" id="22439169" target="_blank">22439169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25266429">
<a name="25266429"></a>Golden NH, Abrams SA, Committee on Nutrition. Optimizing bone health in children and adolescents. <i>Pediatrics</i>. 2014;134(4):e1229-1243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-citrate-pediatric-drug-information/abstract-text/25266429/pubmed" id="25266429" target="_blank">25266429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goltzman.1">
<a name="Goltzman.1"></a>Goltzman D. Treatment of hypocalcemia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goltzman.2">
<a name="Goltzman.2"></a>Goltzman D. Hypoparathyroidism. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 4, 2022b.</div>
</li>
<li>
<div class="reference">
                  Institute of Medicine (IOM). <i>Dietary Reference Intakes for Calcium and Vitamin D</i>. The National Academies Press; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30675420">
<a name="30675420"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). <i>Kidney Int Suppl (2011)</i>. 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-citrate-pediatric-drug-information/abstract-text/30675420/pubmed" id="30675420" target="_blank">30675420</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lo SF. Reference intervals for laboratory tests and procedures. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap. 748.</div>
</li>
<li>
<div class="reference">
                  Lynch R, Wood EG, Neumayr TM. Fluid and electrolyte issues in pediatric critical illness. In: Fuhrman B, Zimmerman J, eds.<i> Pediatric Critical Care</i>. 5th ed. Elsevier Health; 2017:1007-1025.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29848235">
<a name="29848235"></a>Orloff LA, Wiseman SM, Bernet VJ, et al. American Thyroid Association statement on postoperative hypoparathyroidism: diagnosis, prevention, and management in adults. <i>Thyroid</i>. 2018;28(7):830-841. doi:10.1089/thy.2017.0309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-citrate-pediatric-drug-information/abstract-text/29848235/pubmed" id="29848235" target="_blank">29848235</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Root AW. Disorders of mineral metabolism II. Abnormalities of mineral homeostasis in the newborn, infant, child, and adolescent. In: Sperling MA, ed. <i>Pediatric Endocrinology</i>. 5th ed. Elsevier; 2020:chap. 20.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17507729">
<a name="17507729"></a>Straub DA. Calcium supplementation in clinical practice: a review of forms, doses, and indications. <i>Nutr Clin Pract</i>. 2007;22(3):286-296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-citrate-pediatric-drug-information/abstract-text/17507729/pubmed" id="17507729" target="_blank">17507729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22675062">
<a name="22675062"></a>Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline.<i> J Clin Endocrinol Metab</i>. 2012;97(6):1802-1822. doi:10.1210/jc.2011-3045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-citrate-pediatric-drug-information/abstract-text/22675062/pubmed" id="22675062" target="_blank">22675062</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12867 Version 204.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
